Sepsis Diagnostics Market: Global Industry Analysis and Forecast (2022-2029) Trends, Statistics, Dynamics, Segmentation

The Sepsis Diagnostics Market was valued at US$ 600 Mn. in 2021. Global Sepsis Diagnostics Market size is expected to grow at a CAGR of 7.17 % through the forecast period.

Sepsis Diagnostics Market Overview:

When the body reacts to an infection by damaging its tissues, it develops sepsis, a potentially fatal condition. Organs perform badly and inappropriately when the body's infection-fighting mechanisms are activated. Septic shock can develop from sepsis. This sharp drop in blood pressure can cause serious organ damage and even death. Sepsis diagnosis requires symptoms of infection, such as altered mental status, systolic blood pressure, and respiration rate. Sepsis most frequently affects patients who are or have just been hospitalized. Infections that can result in sepsis are more likely to occur in patients in an intensive care unit. In addition to a blood test, further lab tests are required for the diagnosis of sepsis. Infection, clotting issues, irregular liver or kidney function, decreased oxygen availability, and electrolyte abnormalities are all tested using blood samples. Sepsis patients need to be closely monitored and treated in an intensive care unit of a hospital. For respiration and cardiac function to be stabilized, life-saving procedures may be required. Sepsis Diagnostics Market To know about the Research Methodology :- Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022 to 2029. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years' trends are considered while forecasting the market through 2029. 2020 is a year of exception and analysis especially with the impact of lockdown by region.

Sepsis Diagnostics COVID 19 Insights:

The COVID-19 pandemic had a somewhat favorable impact on the need for sepsis diagnostics. The emergence of sepsis cases among covid-19 patients and the widespread distribution of COVID-19 are likely to raise the need for prompt diagnosis and speed up the use of tools, reagents, and test kits for sepsis detection. Lockdowns brought on by the epidemic prevented people from getting health checks, which had an impact on the volume of tests run and reagent sales. The present COVID-19 pandemic has brought attention to the risk that older persons face since they are more prone to consequences, such as acute respiratory distress syndrome, which is typically brought on by pneumonia and raises the possibility of developing sepsis. Consequently, there is a greater requirement for early sepsis detection in individuals with COVID-19 infections.

Sepsis Diagnostics Market Dynamics:

Increasing incidence of hospital-acquired infections Nosocomial infections, sometimes referred to as hospital-acquired infections or HAIs, are the world's leading cause of morbidity and mortality. The most typical hospital-acquired infections (HAIs) are pneumonia, sepsis, and urinary tract infections. In immune-compromised individuals, geriatric patients, and people with chronic conditions, HAIs can result in sepsis. Sepsis among hospitalized patients is becoming more common in the US, increasing by 8.7% annually. Sepsis among hospitalized patients is thought to occur more than 1,000,000 times a year nationwide. The market for sepsis diagnostic products is estimated to grow through the forecast period as a result of the sharp rise in HAIs everywhere. Costly automated diagnostic equipment When compared to blood culture tests, which can be purchased for as little as USD 28–35, the price of molecular diagnostic testing is between $300 and $3,000, which is extremely exorbitant. Companies concentrate on creating molecular diagnostics-based automated diagnostic tools for sepsis detection, however, government hospitals (particularly in developing countries) and academic research labs cannot afford such systems due to budgetary constraints. Becoming a significant element in the market for sepsis diagnostics' slow growth. The creation of quick diagnostic methods and point-of-care tests for sepsis Sepsis is a highly challenging condition to detect, and in septic shock patients with hypertension, the risk of mortality rises by 7.6% with even a 1-minute delay in antibiotic delivery. Thus, it is more important than ever to make a quick diagnosis of sepsis to speed up the administration of antibiotics to sepsis patients. Many sepsis diagnostic vendors are extending the range of products they offer for point-of-care sepsis detection, speeding up diagnosis overall. The automated microbiological detection technique offered by the BACTEC Plus, BacT/Alert, and BACTEC FX blood culturing devices developed by BD Company (US) provide a quick diagnosis of sepsis in three hours. Lack of qualified healthcare workers Sepsis is a potentially fatal condition that requires prompt diagnosis and treatment from trained medical personnel. Only 50% of patients with severe sepsis conveyed by the EMS system had a paramedic, which raises serious concerns about the talent development deficit. Each stage of patient treatment is impacted by a shortage of qualified paramedics, including sepsis awareness, sepsis screening, and making an accurate diagnosis.

Sepsis Diagnostics Market Segment Analysis:

Based on Product, The blood culture media segment is dominating the market with a 45.5% share. The segment is expected to keep up its lead through the forecast period. This is because clinicians view blood cultures as the most practical and economical testing method. The world market has been divided into three product categories based on products: equipment, blood culture media, and test kits & reagents. In a study on sepsis patients in Thailand, it was found that the Septifast assay, a PCR-based technique, provided superior diagnostic performance than blood culture. A consistent growth rate is expected to be seen in the instruments market through the forecast period as a result of rising public awareness of healthcare issues and an increase in the number of surgical procedures. For instance, Wolters Kluwer's POC Advisor was implemented by Guthrie, a U.S.-based integrated health care system, in September 2021 for sepsis diagnosis and management at four local hospitals. Sepsis Diagnostics Market Based on the Technology, The microbiological technology category is dominating the market with a 48.5% share. This might be linked to the fact that the use of culture medium tests in microbiology technology enables precise detection and identification of bacteria for sepsis diagnosis. New strategic initiatives by important players are also fuelling the segment's growth. For instance, in April 2021, BD introduced its brand-new BD BACTEC platelet quality control media, which aids in the detection and reduction of sepsis among patients getting platelet transfusions. The market is divided into four categories based on technology: microbiology, molecular diagnostics, immunoassays, and flow cytometry. The molecular diagnostics segment is expected to grow at the quickest CAGR through the forecast period. The segment is expected to be driven by the adoption of molecular diagnostic technology because of its many benefits, including high sensitivity, accuracy, and quick turnaround times compared to other technologies. This technique's drawback is that it is unable to detect organisms that are impossible to cultivate. Nevertheless, following blood culture, the molecular diagnostics method is regarded as a standard method for identifying pathogens. Based on the Pathogen, The bacterial Sepsis Segment is dominating the market with a 79.5% share and is expected to keep leading during the forecast period due to an increase in bacterial sepsis cases, an increase in hospital-transmitted infections, and an increase in surgical operations. Bacterial sepsis is the most prevalent form, with 62.2 % of patients infected with gram-negative bacteria and 46.8 % with gram-positive bacteria, as per a report released by SAGE Journals. The market is divided into categories for bacterial sepsis, fungal sepsis, and other pathogen-based sepsis. Gram-negative bacteria sub-segment will lead the market in the bacterial sepsis segment through the forecast period. Despite having a smaller market share, the fungal sepsis category is expected to retain a sizable CAGR during the forecast period. The growing availability and release of a wide variety of innovative sepsis diagnosis instruments for pathogen detection are one of the key factors driving the pathogen segment. The more advanced technology markets in North America and Europe are where these products are most frequently introduced. Intensifying regulatory approvals of novel solutions and robust R&D initiatives are expected to promote segment growth

Sepsis Diagnostics Market Regional Insights:

North America led the world market and had a revenue share of more than 39.7 %. it is expected that the region would keep up its lead through the forecast period. This development can be linked to the region's increased use of advanced diagnostic tools due to the presence of strong healthcare infrastructure. Additionally, the market growth in this area is being fuelled by the substantial presence of important competitors and a favourable reimbursement system. Additionally, it is expected that the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods. It is expected that Europe holds the second-largest market share for sepsis diagnostics. This region is expected to expand at a CAGR of 7.25 % during the forecast period. The market will benefit from the expanding use of new technologies and investments in research & development from various economies. Asia Pacific region is expected to grow fast during the forecast period. Due to the rising demand for sepsis diagnostic tools in nations with high rates of infectious diseases, like Algeria and Morocco, Middle East Africa is expected to experience significant growth during the forecast period. This region's profitable growth is also thought to be a result of the rise in European and international businesses' initiatives to increase access to cutting-edge laboratory automation technologies. However, the lack of awareness in some of the developing nations may somewhat limit sales growth. The objective of the report is to present a comprehensive analysis of the global Sepsis Diagnostics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Sepsis Diagnostics Market dynamic, structure by analyzing the market segments and projecting the Sepsis Diagnostics Market size. Clear representation of competitive analysis of key players by Product type, price, financial position, product portfolio, growth strategies, and regional presence in the Sepsis Diagnostics Market make the report investor’s guide.

Sepsis Diagnostics Market Scope: Inquire before buying

Global Sepsis Diagnostics Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 600 Mn.
Forecast Period 2022 to 2029 CAGR: 7.17% Market Size in 2029: US $ 1120 Mn.
Segments Covered: by Product • Instruments • Blood Culture Media • Assay Kits and Reagents
by Technology • Microbiology • Molecular Diagnostics • Immunoassays • Flow Cytometry
by Pathogen • Bacterial Sepsis • Gram-positive Bacteria • Gram-negative Bacteria • Fungal Sepsis • Others
by Testing Type • Laboratory Testing • PoC Testing

Sepsis Diagnostics Market by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Sepsis Diagnostics Market Key Players

• Scotland (US) • Sandstone Diagnostics Inc. (US) • T2 Biosystems Inc. (US) • Immunexpress (US) • Axis-Shield Diagnostics Ltd. (Scotland) • Becton Dickinson and Company (US) • EKF Diagnostics (UK) • Cube Dx GmbH (Austria) • Wolters Kulwer N.V. (Netherlands) • Amara Health (US) • bioMérieux SA (France) • F. Hoffmann-La Roche AG (Switzerland) • Luminex Corp. (US) • Bruker Corp. (US) Frequently Asked Questions: 1] What segments are covered in the Global Sepsis Diagnostics Market report? Ans. The segments covered in the Sepsis Diagnostics Market report are based on Product, Technology, Pathogen, and Testing Type. 2] Which region is expected to hold the highest share in the Global Sepsis Diagnostics Market? Ans. The North America region is expected to hold the highest share in the Sepsis Diagnostics Market. 3] What is the market size of the Global Sepsis Diagnostics Market by 2029? Ans. The market size of the Sepsis Diagnostics Market by 2029 is expected to reach US$ 1.12 Bn. 4] What is the forecast period for the Global Sepsis Diagnostics Market? Ans. The forecast period for the Sepsis Diagnostics Market is 2022-2029. 5] What was the market size of the Global Sepsis Diagnostics Market in 2021? Ans. The market size of the Sepsis Diagnostics Market in 2021 was valued at US$ 0.60 Bn.
1. Global Sepsis Diagnostics Market Size: Research Methodology 2. Global Sepsis Diagnostics Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Sepsis Diagnostics Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Sepsis Diagnostics Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Sepsis Diagnostics Market Size Segmentation 4.1. Global Sepsis Diagnostics Market Size, by Product (2021-2029) • Instruments • Blood Culture Media • Assay Kits and Reagents 4.2. Global Sepsis Diagnostics Market Size, by Technology (2021-2029) • Microbiology • Molecular Diagnostics • Immunoassays • Flow Cytometry 4.3. Global Sepsis Diagnostics Market Size, by Pathogen (2021-2029) • Bacterial Sepsis • Gram-positive Bacteria • Gram-negative Bacteria • Fungal Sepsis • Others 4.4. Global Sepsis Diagnostics Market Size, by Testing Type (2021-2029) • Laboratory Testing • PoC Testing 5. North America Sepsis Diagnostics Market (2021-2029) 5.1. North America Sepsis Diagnostics Market Size, by Product (2021-2029) • Instruments • Blood Culture Media • Assay Kits and Reagents 5.2. North America Sepsis Diagnostics Market Size, by Technology (2021-2029) • Microbiology • Molecular Diagnostics • Immunoassays • Flow Cytometry 5.3. North America Sepsis Diagnostics Market Size, by Pathogen (2021-2029) • Bacterial Sepsis • Gram-positive Bacteria • Gram-negative Bacteria • Fungal Sepsis • Others 5.4. North America Sepsis Diagnostics Market Size, by Testing Type (2021-2029) • Laboratory Testing • PoC Testing 5.5. North America Sepsis Diagnostics Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Sepsis Diagnostics Market (2021-2029) 6.1. European Sepsis Diagnostics Market, by Product (2021-2029) 6.2. European Sepsis Diagnostics Market, by Technology (2021-2029) 6.3. European Sepsis Diagnostics Market, by Pathogen (2021-2029) 6.4. European Sepsis Diagnostics Market, by Testing Type (2021-2029) 6.5. European Sepsis Diagnostics Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Sepsis Diagnostics Market (2021-2029) 7.1. Asia Pacific Sepsis Diagnostics Market, by Product (2021-2029) 7.2. Asia Pacific Sepsis Diagnostics Market, by Technology (2021-2029) 7.3. Asia Pacific Sepsis Diagnostics Market, by Pathogen (2021-2029) 7.4. Asia Pacific Sepsis Diagnostics Market, by Testing Type (2021-2029) 7.5. Asia Pacific Sepsis Diagnostics Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Sepsis Diagnostics Market (2021-2029) 8.1. Middle East and Africa Sepsis Diagnostics Market, by Product (2021-2029) 8.2. Middle East and Africa Sepsis Diagnostics Market, by Technology (2021-2029) 8.3. Middle East and Africa Sepsis Diagnostics Market, by Pathogen (2021-2029) 8.4. Middle East and Africa Sepsis Diagnostics Market, by Testing Type (2021-2029) 8.5. Middle East and Africa Sepsis Diagnostics Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Sepsis Diagnostics Market (2021-2029) 9.1. South America Sepsis Diagnostics Market, by Product (2021-2029) 9.2. South America Sepsis Diagnostics Market, by Technology (2021-2029) 9.3. South America Sepsis Diagnostics Market, by Pathogen (2021-2029) 9.4. South America Sepsis Diagnostics Market, by Testing Type (2021-2029) 9.5. South America Sepsis Diagnostics Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Scotland 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Sandstone Diagnostics Inc. 10.3. T2 Biosystems Inc. 10.4. Immunexpress 10.5. Axis-Shield Diagnostics Ltd. 10.6. Becton Dickinson and Company 10.7. EKF Diagnostics 10.8. Cube Dx GmbH 10.9. Wolters Kulwer N.V. 10.10. Amara Health 10.11. bioMérieux SA 10.12. F. Hoffmann-La Roche AG 10.13. Luminex Corp. 10.14. Bruker Corp.

About This Report

Report ID 112617
Category Healthcare
Published Date July 2022
Updated Date
Contact Us